The applicability of this sign seems to be limited to lower-grade gliomas, albeit constituting a highly specific imaging biomarker for the IDH-MUT 1p/19q non-codeleted molecular subtype [22,37,38,39,40]. This evidence concerns the gene IDH2 and central nervous system cancer.